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Abstract
The minor allele of rs11136000 within CLU is strongly associated with reduced Alzheimer’s disease (AD) risk. The mechanism
underlying this association is unclear. Here, we report that CLU1 and CLU2 are the two primary CLU isoforms in human brain;
CLU1 and CLU2 share exons 2–9 but differ in exon 1 and proximal promoters. The expression of both CLU1 and CLU2 was
increased in individuals with significant AD neuropathology. However, only CLU1 was associated with the rs11136000
genotype, with the minor ‘‘protective’’ rs11136000T allele being associated with increased CLU1 expression. Since CLU1 and
CLU2 are predicted to encode intracellular and secreted proteins, respectively, we compared their expression; for both CLU1
and CLU2 transfected cells, clusterin is present in the secretory pathway, accumulates in the extracellular media, and is
similar in size to clusterin in human brain. Overall, we interpret these results as indicating that the AD-protective minor
rs11136000T allele is associated with increased CLU1 expression. Since CLU1 and CLU2 appear to produce similar proteins
and are increased in AD, the AD-protection afforded by the rs11136000T allele may reflect increased soluble clusterin
throughout life.
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Introduction
Clusterin (CLU, APOJ) has been implicated in diseases ranging
from cancer to Alzheimer’s disease (AD) (reviewed in [1,2,3,4]).
Although the primary role of clusterin in AD is unclear, CLU is
implicated in AD by several lines of evidence, including (I) CLU
mRNA and clusterin protein is increased in AD [5,6], (ii) clusterin
is a component of plaques [4,5,7], (iii) clusterin modulates AD-
related pathways such as inflammation and apoptosis [1,8,9] and
(iv) clusterin acts as an amyloid-beta (Aß) chaperone to alter Aß
aggregation and/or clearance ([10,11], reviewed in [4,12,13,14]).
The physiologic relevance of CLU to AD was confirmed recently
when CLU single nucleotide polymorphisms (SNP)s were associ-
ated with AD risk [15,16,17,18,19]. Overall, CLU genetic
variation is essentially unequivocally associated with AD given
the robust statistical power of the initial genome-wide association
studies and subsequent replication studies [15,16,17,18,19]. How
CLU SNPs modulate clusterin to alter AD risk is unknown.
Two CLU isoforms, CLU1 and CLU2, have been reported that
consist of nine exons and differ only in their first exons and
associated proximal promoters; CLU1 is predicted to encode a
nuclear protein and CLU2 a secreted protein (reviewed in [20]).
Additional reported isoforms include a CLU isoform that lacks
exon 5 and a CLU isoform that lacks exon two, which encodes the
leader sequence, resulting in another nuclear clusterin [21,22].
Here, we investigated the hypothesis that CLU isoforms are
differentially modulated by AD status and AD-associated SNPs.
We identified CLU1 and CLU2 as the major CLU isoforms in
human brain. Quantitative expression studies show that both
CLU1 and CLU2 are increased in AD but only CLU1 is associated
with rs11136000. Lastly, although CLU1 and CLU2 are predicted
to produce intracellular and secreted proteins, respectively,
immunofluorescence and Western blot studies indicate that
CLU1 and CLU2 both produce secreted proteins that are similar
to those detected in the human brain. Overall, we interpret our
results as suggesting that SNP-mediated increases in secreted,
soluble clusterin expression may act to reduce AD risk.
Methods
Ethics Statement
The work described here was performed with approval from the
University of Kentucky Institutional Review Board.
Cell Culture
SH-SY5Y (human neuroblastoma) and HepG2 (human hepa-
tocellular carcinoma) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 50 U/ml penicillin and 50 mg/ml streptomycin at
37uC in a humidified 5% CO2 - 95% air atmosphere.
CLU Expression Plasmid
Expression plasmids encoding CLU1 and CLU2 were generated
from SH-SY5Y cellular mRNA that was reverse transcribed by
using the primer 59-TAGGTGCAAAAGCAACAT-39 which
corresponds to sequence just after the CLU stop codon. CLU1
and CLU2 cDNAs were then amplified by PCR with forward
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primers 59-TGAGTCATGCAGGTTTGCAG-39 (CLU1) and 59-
ATGATGAAGACTCTGCTGCTG-39 (CLU2) used in combina-
tion with the common reverse primer 59-CTCCTCCCG-
GTGCTTTTTG-39. PCR fragments were ligated into pcDNA3.1/
V5-His-TOPO T/A cloning vector (Invitrogen, Carlsbad, CA).
Clones encoding CLU1 and CLU2 were detected by PCR
screening and clone integrity confirmed by sequencing.
Human Autopsy Tissue
De-identified human brain specimens were provided by the
University of Kentucky AD Center Neuropathology Core [23,24].
AD and non-AD designations followed NIARI neuropathology
guidelines, which include indices of neuritic senile plaques and
neurofibrillary tangles, and provide a likelihood staging of AD
neuropathological diagnosis [25,26]. Individuals with ‘‘low’’ AD
neuropathology were cognitively intact prior to death and had no
or low likelihood of AD by NIARI criteria; their average age at
death was 81.8610.2 (mean 6SD, n= 17). Individuals with
‘‘high’’ AD neuropathology represented a combination of
demented individuals with high likelihood of AD by NIARI
criteria (n = 27) and cognitively intact individuals that were found
to have moderate or high AD neuropathology at death (n = 7);
their average age at death was 81.966.2 (mean6SD, n= 34). The
average post-mortem interval (PMI) for low AD neuropathology
individuals was 3.060.8 hours (mean 6 SD, n= 17) while the
PMI for high AD neuropathology individuals was similar
(3.260.8 hours (n = 34)). Choroid plexus samples were from six
individuals with an average age at death of 80.06 3.3 years and
PMI of 2.961.1 hours. Fetal tissue RNA samples were obtained
commercially (Stratagene, Santa Clara, CA) and have been
described previously [27].
PCR Amplification
Total RNA was extracted from human brain specimens and
converted to cDNA in 1 mg aliquots with random hexamers and
reverse transcriptase (SuperScript III, Invitrogen), essentially as we
described previously [24,28,29,30]. PCR primers were designed
such that the splicing of each internal CLU exon as well as CLU1
and CLU2 were evaluated (Table 1). In initial screening, cDNA
pooled from five high AD neuropathology and five low AD
neuropathology samples were subjected to PCR-amplification
(Platinum Taq, Invitrogen) by using each primer pair and a PCR
profile consisting of initial denaturation for 5 minutes at 95uC,
followed by 27–32 cycles of 94uC for 30 s, 60uC for 30 s, and
72uC for 1 min, and final extension at 72uC for 7 min (Perkin
Elmer 9600). PCR products were separated by polyacrylamide gel
electrophoresis, stained with SYBR Gold and visualized by using a
fluorescence imager (Fuji FLA-2000). The identity of the PCR
products was confirmed by direct sequencing (Davis Sequencing,
Davis, CA).
Real-time PCR
The expression level of CLU1 and CLU2 was quantified by real-
time PCR. Each isoform was specifically amplified by using a sense
primer corresponding to sequence within their respective exon 1,
i.e., 59-GCGAGCAGAGCGCTATAAAT-39 for CLU1 and 59-
AGATGGATTCGGTGTGAAGG-39 for CLU29, and an anti-
sense primer corresponding to sequence at the exon 2–3
boundary, i.e., 59-GACATTTCCTGGAGCTCATTG-39. Note
that the CLU1 sense primer contains the TATA sequence
suggested by Schepeler et al to be present only in a longer
‘‘CLU34’’ isoform [31]. The 20 ml real-time PCR mixture
containing approximately 20 ng of brain cDNA, 1 mM of each
primer and 16 PerfecTaq PCRSupermix (Quanta Biosciences,
Gaithersburg, MD) was subjected to real-time PCR (Bio-Rad,
Hercules, CA). PCR profiles consisted of pre-incubation at 95uC
for 2 min, followed by 40 cycles of 95uC for 15 s, 60uC for 30 s,
and 72uC for 20 s. Specificity of the reactions was evaluated by
showing a single PCR product by gel electrophoresis and by
performing a melting curve analysis after PCR amplification. The
PCR product copy number in each sample was determined
relative to standard curves that were amplified in parallel and were
based upon previously purified and quantified PCR products. The
copy numbers were then normalized to the geometric mean of the
copy numbers of hypoxanthine-guanine phosphoribosyltransferase
1 and ribosomal protein L13A as described (Vandesompele et al.,
2002; Zhang et al., 2005). All real-time PCR assays were repeated
twice.
Genotyping
DNA samples were genotyped for rs11136000 by using
unlabeled PCR primers and TaqMan FAM and VIC dye-labeled
MGB probes (Pre-designed SNP Genotyping Assay, Applied
Biosystems, Foster City, CA) on a real-time PCR machine (Bio-
Rad, Hercules, CA).
Statistical Analysis
Variation in CLU isoform expression were analyzed as a
function of rs11136000 genotype, AD neuropathology, sex and
age by using a general linear model (SPSS v.18 (IBM, Somers,
NY)). A dominant mode of inheritance was assumed to maximize
statistical power.
Immunofluorescence
CLU expression plasmids were transfected into SH-SY5Y cells
by using FuGene HD Transfection Reagent as directed by the
manufacturer (Roche Applied Sciences, Indianapolis, IN). Briefly,
3.756104 cells/well were maintained in a poly-L-lysine treated 8-
well chamber coverglass (Lab-Tek, Nunc, Rochester, NY) and
transfected the next day with CLU1 or CLU2 expression plasmid.
Twenty-four hours after transfection, cells were washed with
phosphate buffered saline (PBS) and fixed with ice-cold methanol
for 5 minutes. Non-specific antibody binding sites were blocked by
incubating the cells with 5% goat serum in PBS with 0.1% Tween-
20 (PBST) for 1 hour and the cells were then incubated with
mouse anti-V5 antibody (1:1000 dilution, ab27671, Abcam,
Cambridge, MA) and either rabbit anti-calnexin antibody (1:200
dilution, SPA-860, Stressgen, Victoria, BC, Canada) or rabbit
Table 1. PCR Primers for evaluating splice variation.
Exons
Amplified
Product
Size Primer Primer Sequence
1a-5
(For CLU1)
596 bp Exon 1a Forward GCGAGCAGAGCGCTATAAAT
Exon 5 Reverse GATGCGGTCACCATTCATC
1b-5
(For CLU2)
567 bp Exon 1b Forward AGATGGATTCGGTGTGAAGG
Exon 5 Reverse GATGCGGTCACCATTCATC
4–6 598 bp Exon 4 Forward AGAGTGTAAGCCCTGCCTGA
Exon 6 Reverse AGACAAGATCTCCCGGCACT
5–9 675 bp Exon 5 Forward GGACATCCACTTCCATAGCC
Exon 9 Reverse ACTTGGTGACGTGCAGAGC
doi:10.1371/journal.pone.0033923.t001
AD SNP and CLU Isoform Expression
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anti-TGN46 antibody (1:1000 dilution, ab16052, Abcam) in 5%
goat serum at 4uC overnight. The next day, cells were washed with
PBST three times and incubated with a mixture containing Alexa-
488 goat anti-mouse IgG antibody (1:200 dilution, Molecular
Probes, Carlsbad, CA) and Alexa-568 goat anti-rabbit IgG
antibody (1:200 dilution, Molecular Probes) in 5% goat serum at
room temperature for an hour. After washing with PBST, cells
were stained with 10 mg/ml of Hoechst 33258 (Molecular Probes)
for 30 minutes, washed with PBS, and subjected to fluorescence
microscopy.
Western Blot
SH-SY5Y cells or HepG2 cells were grown in a 100 mm dish
(2.66106 cells/dish) for 24 hours and then transfected with CLU1
or CLU2 expression plasmid by using FuGene HD Transfection
Reagent as directed by the manufacturer (Roche Applied
Sciences). Twenty-four hours after transfection, cell medium was
replaced with Opti-MEM (Invitrogen) and cells maintained for
another 24 hours. The conditioned medium was collected and the
cells washed with 5 ml of room-temperature PBS. Cells were then
lysed in 0.5 ml of RIPA butter (50 mM Tris, pH 8.0, 150 mM
NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) containing
16 protease inhibitor cocktail (Roche Applied Sciences) for
30 minutes on ice with occasional rocking. Cell lysates were
centrifuged at 10,0006g for 10 minutes at 4uC and the
supernatant collected. Conditioned medium was centrifuged at
2506g for 10 minutes and 0.5 ml of the supernatant was collected
and supplemented with 16 protease inhibitor cocktail (Roche
Applied Science). Human brain anterior cingulate tissue samples
were prepared by homogenizing ,0.5 mg tissue in RIPA buffer
supplemented with 16 protease inhibitor cocktail, centrifuging at
14,0006g for 10 minutes at 4uC, and then collecting the
supernatant. After the protein concentration of each sample was
determined (Micro BCA Protein Assay Reagent Kit, Pierce,
Rockford, IL), 15 or 20 mg protein were mixed with SDS sample
loading buffer containing b-mercaptoethanol, boiled for 5 minutes
and subjected to polyacrylamide gel electrophoresis on a 7.5%
polyacrylamide gel. Proteins were transferred to nitrocellulose
membranes (Bio-Rad). The blots were then incubated with 5%
nonfat dry milk for 1 hour at room temperature and probed
overnight with mouse anti-V5 antibody (1:5000 dilution, Abcam)
or mouse anti-clusterin antibody (1:200, B-5 Santa-Cruz) at 4uC.
After washing with PBST four times for 5 minutes each, the blots
were incubated with peroxidase-conjugated sheep anti-mouse
antibody (1:1,000 dilution, Jackson ImmunoResearch) for 1 hour
at room temperature. Bound peroxidase was visualized by using a
SuperSignal West Pico kit (Pierce) and a molecular imager
(ChemiDoc XRS System, Bio-Rad). For studies involving PNGase
F digestion, each protein sample was treated with PNGase F as
directed by the manufacturer (New England Biolabs, Ipswich,
MA). Briefly, 15 mg protein of each sample was denatured at
100uC for 10 minutes and incubated with 1,500 units of PNGase F
at 37uC for 2 hours. Samples were then analyzed by Western blot
as described above.
Results
To begin to evaluate CLU expression, we screened human brain
cDNA to identify CLU isoforms present in brain. Previously
reported isoforms include CLU1 and CLU2, which are identical in
exons 2–9 but differ in exon 1, as well as isoforms lacking exons 2
or 5 ([21,22], reviewed in [20]). RT-PCR analyses of pooled
human brain cDNA samples detected only CLU1 and CLU2
(Figure 1A–1B). CLU2 translation is predicted to result in a
secreted protein, beginning at the initial ATG in exon 2 that is
common to both CLU2 and CLU1 (Figure 1C). In contrast, CLU1
translation is predicted to initiate at an ATG within its exon 1,
which is in-frame with the ATG site in the common exon 2.
Hence, CLU1 is predicted to encode a protein identical to that
encoded by CLU2 except that the CLU1 protein would contain 52
additional amino acids at its amino terminus (Figure 1C). This
change is predicted by PSORTII to result in an intracellular and
likely nuclear, form of clusterin (reviewed in [20]). In summary,
CLU1 and CLU2 are the primary CLU isoforms in brain and are
predicted to encode intracellular and secreted proteins, respec-
tively.
To evaluate whether rs11136000, the primary AD-related CLU
SNP [15,16,17,18,19], is associated with CLU expression, we
quantified CLU1 and CLU2 expression in a series of brain samples.
The CLU isoforms were quantified in separate real-time PCR
assays that used forward primers corresponding to their unique
exon 1 and a common reverse primer that targeted the exon 2–3
boundary. Copy numbers were determined relative to a standard
curve for each isoform and normalized to the geometric mean of
housekeeping genes [23,32]. The expression of CLU1 and CLU2
were modestly coordinately regulated (Figure 2A), with CLU2
being consistently greater than CLU1; the overall CLU2: CLU1
ratio was 3.3561.84 (mean6 SD, n= 51). To gain further insights
into CLU isoform expression, we quantified CLU1 and CLU2 in a
series of single human fetal tissue samples as well as a set of six
adult choroid plexus samples (Figure 2B). Among the fetal tissues,
the CLU2: CLU1 ratio varied widely from 0.3 (skin) to 6.2 (kidney)
(Figure 2B). The CLU2:CLU1 ratio in choroid plexus, which
produces cerebrospinal fluid, was 5.7260.65 (mean 6 SD, n= 6).
We next evaluated CLU isoform expression as a function of AD
neuropathology, rs11136000 status, sex and age. We found that
CLU1 expression was significantly increased with high AD
neuropathology and the minor rs11136000T allele (Figure 2C,
Table 2). In contrast, CLU2 expression was significantly increased
with AD neuropathology but not rs11136000 genotype, and
decreased with age (Figure 2D–E, Table 3). Overall, both CLU1
and CLU2 expression was increased with AD, confirming prior
reports. However, only CLU1 expression was associated with
rs11136000. Since the minor rs11136000T allele was associated
with both increased CLU1 expression and reduced AD risk
[15,16,17,18,19], we interpret these results as suggesting that
increased CLU1 expression is associated with reduced AD risk.
CLU1 and CLU2 are predicted to encode intracellular and
secreted proteins, respectively (Figure 1). Therefore, we evaluated
the proteins produced by CLU1 and CLU2 transfected cells to
discern whether these corresponded to the intracellular and
secreted forms of clusterin that have been reported [4,8,33]. When
each isoform was transiently transfected into neural SH-SY5Y
cells, immunofluorescence analyses showed a similar subcellular
localization pattern (Figure 3). The proteins produced by CLU1
and CLU2 tended to concentrate within the Golgi apparatus, as
established by double-labeling with an antibody against trans-
Golgi network protein 46 (TGN46) (Figure 3A). Relatively modest
amounts of clusterin were also detected within the endoplasmic
reticulum (ER), as established by double labeling with calnexin
(Figure 3B). Nuclear, cytosolic, or mitochondrial-associated
clusterin was not observed. Hence, the clusterin produced by
CLU1 and CLU2 manifests an intracellular localization that
includes the ER and Golgi, consistent with a possible secretory
pathway for both proteins.
CLU1 is predicted to encode a 501 amino acid protein with a
molecular weight of 57.8 kDa while CLU2 is predicted to encode
449 amino acids, totaling 52.5 kDa. During maturation of secreted
AD SNP and CLU Isoform Expression
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Figure 1. CLU1 and CLU2 are the primary CLU isoforms expressed in human brain. The exon layout for the CLU1 and CLU2 isoforms is shown
(A). Coding and non-coding exonic regions are represented by black and white boxes, respectively, while introns are shown as thin black lines. The
first ATG site in each isoform is shown as well. Evaluation of CLU splicing by RT-PCR identified only CLU1 and CLU2 in human brain cDNA (B), i.e., single
PCR products are observed upon amplification from exon 1a – exon 5 (lane 1), exon 1b – exon 5 (lane 2), exon 4 – exon 6 (lane 3) and exon 5 – exon 9
(lane 4). Molecular weight markers are shown at the left. The predicted protein sequences encoded by CLU1 and CLU2, beginning with the initial ATG
sites shown in A, are shown in panel C. The sequence in gray font is unique to CLU1 while sequence in black font is common to CLU1 and CLU2. The
boxed amino acid sequence represents signal sequence that is removed from clusterin-2 upon its translocation to the ER. Two nuclear localization
sequences, as predicted by PSORT II (http://psort.ims.u-tokyo.ac.jp/form2.html), are underlined. The asterisk shows the clusterin cleavage site that
separates the a- and b- subunits.
doi:10.1371/journal.pone.0033923.g001
Figure 2. Expression of CLU isoforms in human tissues. CLU1 and CLU2 isoforms were quantified by isoform-specific RT-PCR in a series of adult
human cingulate and choroid plexus samples (A–B) as well as a human fetal tissues (B). Within A, each marker reflects the expression of CLU1 and
CLU2, normalized to housekeeping genes, in a single brain sample. Within B, the value in parentheses following the tissue name is the CLU1:CLU2
ratio. CLU1 expression shows a positive association with AD neuropathology and rs11136000T allele (C). CLU2 expression was increased in individuals
with AD pathology and decreased with age (D–E).
doi:10.1371/journal.pone.0033923.g002
AD SNP and CLU Isoform Expression
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clusterin, the protein is N-glycosylated and proteolyzed to generate
a heterodimer that is maintained by disulfide bonds [20]. To
compare the size of the proteins produced by CLU1 and CLU2, we
performed Western blot analyses of transfected SH-SY5Y cells;
ectopic clusterin was detected via a V5 epitope tag (Figure 4 A–B).
Cell lysates contained both intact and cleaved clusterin while
conditioned medium contained only cleaved clusterin; the
clusterin protein produced by CLU1 and CLU2 appeared equal
in size (Figure 4A). To discern whether glycosylation differences
may obscure differences in the clusterin molecular weight derived
from their primary sequence, the protein mixtures were digested
with PNGase F to remove N-linked sugars prior to electrophoresis;
the size of the proteins produced by CLU1 and CLU2 transfected
cells were both decreased similarly by PNGase treatment
(Figure 4B). We considered the possibility that CLU translation
may show cell-type specificity, and therefore repeated this study in
an unrelated cell line by transfecting CLU1 and CLU2 into HepG2
cells. As with the SH-SY5Y cells, CLU1 and CLU2 transfected cells
produced clusterin of similar size, even after PNGase F digestion
(Figure 4C). Hence, we found no evidence to suggest that the
proteins produced by CLU1 and CLU2 differ in cellular
localization, size, glycosylation, or proteolytic cleavage. Rather,
when these Western blot studies are considered in combination
with the immunofluorescence studies, CLU1 and CLU2 appear to
produce equivalent proteins that are similarly translated, glycosy-
lated, and cleaved as they pass through the ER and Golgi in the
secretory pathway to the extracellular space.
To evaluate whether the clusterin proteins produced by CLU1
and CLU2 in vitro are similar to those produced in vivo, we
compared ectopic clusterin with endogenous clusterin in SH-
SY5Y cells and in human brain by Western blotting with a
clusterin antibody. Endogenous clusterin in SH-SY5Y cells
migrates at a slightly lower molecular weight than that resulting
from CLU transfection, reflecting the 5.1 kDa V5/His tag encoded
by the pcDNA3.1 vector expressing transfected CLU (Figure 4D).
Importantly, this 5.1 kDa size difference between endogenous and
transfected clusterin is similar to the size difference between the
CLU1 and CLU2-predicted proteins, indicating that if the proteins
encoded by CLU1 and CLU2 differed by 5 kDa, the proteins
would be resolved easily under these experimental conditions. The
endogenous SH-SY5Y clusterin migrates similarly to the intact
protein detected in brain homogenates suggesting these cellular
forms are similar to those present in vivo (Figure 4D). To extend
this analysis to the heterodimeric form of clusterin, we also
performed electrophoresis under non-reducing conditions. We
found that heterodimeric protein from CLU1 and CLU2
transfected cells appeared similar in size to each other and to the
forms found in brain (Figure 4E). Hence, CLU1 and CLU2
produce proteins in vitro that are similar in size to endogenous
clusterin in vitro and human brain.
Discussion
The main findings of this report are several. First, CLU1 and
CLU2 are the primary CLU isoforms in human brain and differ in
their first exon and proximal promoter. Second, the expression of
only CLU1 was associated with rs11136000 while both CLU1 and
CLU2 were increased with robust AD neuropathology. Third,
CLU1 and CLU2 produce secreted clusterin proteins that are
similar to each other and to clusterin in human brain. Since CLU is
increased in AD and CLU1 is increased with the minor
rs11136000T allele, which is also associated with reduced AD
risk, we interpret our results as suggesting that increased CLU
expression throughout life may reduce AD risk. Overall, these
results identify a possible means underlying the association of
rs11136000 with AD risk.
The association between CLU expression and rs11136000 was
discerned because the CLU isoforms were analyzed separately. For
example, when we analyzed total CLU expression in the same
fashion as reported here, total CLU was not associated with
rs11136000 (p = 0.51) although a robust association with AD
pathology was observed (p = 0.005, Ling et al., unpublished
observations). The lack of a significant association between
rs11136000 and total CLU is somewhat disconcerting since
CLU1 and CLU2 appear to produce a similar protein. We
speculate that (i) the threshold for clusterin biological significance
may be less than the threshold for overall CLU statistical
significance and/or (ii) CLU1 may be enriched in a cell type
different than CLU2, which may affect its functionality. We note
that the lack of an association between total CLU and rs11136000
was similar to prior reports that total CLU mRNA or clusterin
protein were not associated with rs11136000 [17,34]. As the
clusterin produced by CLU1 and CLU2 appears similar, discerning
an association between rs11136000 and clusterin would be
especially challenging in tissues with a large proportion of CLU2.
In this regard, CLU2 was the major isoform in choroid plexus,
suggesting that an association between cerebrospinal fluid clusterin
and rs11136000 would be difficult to detect. The differential
regulation of CLU1 and CLU2 was not unexpected because CLU1
and CLU2 have separate proximal promoter regions. Consistent
with this observation, Cochrane et al found that androgen-
treatment in a prostate cancer cell line decreased CLU1 expression
while enhancing CLU2 expression [35]. Although the identifica-
tion of the functional SNPs and transcription factors that modulate
Table 2. Analysis of CLU1 Expression.
Parameter Coeff. SE P value
AD Neuropathology 0.01675 0.00551 0.004
Rs11136000 (dominant model) 0.01927 0.00798 0.020
Sex 20.00708 0.01503 0.640
Age 20.00112 0.00104 0.286
CLU1 expression was analyzed as a function of rs1136000, AD neuropathology,
sex and age by using a general linear model. This model assumed a dominant
mode of inheritance for the SNP. The estimated marginal means for CLU1 in
rs11136000 CC versus CT/TT individuals were 0.11260.013 and 0.15160.010
(mean 6 SE), respectively. The estimated marginal means for low and high AD
neuropathology were 0.10660.014 and 0.15760.009 (mean 6SE), respectively.
These values were modeled with age equal to 82.3 years.
doi:10.1371/journal.pone.0033923.t002
Table 3. Analysis of CLU2 Expression.
Parameter Coeff. SE P value
AD Neuropathology 0.06482 0.02483 0.012
Rs11136000 (dominant model) 0.00697 0.03594 0.847
Sex 0.03399 0.06766 0.618
Age 20.01024 0.00467 0.033
CLU2 expression was analyzed as a function of rs1136000, AD neuropathology,
sex and age by using a general linear model. A dominant mode of inheritance
was assumed for rs11136000. The estimated marginal means for low and high
AD neuropathology were 0.33260.062 and 0.52660.041 (mean 6SE),
respectively. These values were modeled with age equal to 82.3 years.
doi:10.1371/journal.pone.0033923.t003
AD SNP and CLU Isoform Expression
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CLU expression is beyond the scope of this report, we note that
rs11136000 resides within intron 3 and is common to both CLU1
and CLU2. Hence, rs11136000 is likely not functional but rather is
in linkage with a functional SNP more proximal to the CLU1
promoter. In summary, the association between rs11136000 and
CLU1 was dependent upon analyzing the two CLU isoforms
separately.
Since earlier predictions were that CLU2 encodes a secreted
protein while the additional 52 amino-terminal residues encoded
by CLU1 would result in its intracellular localization [20], we
expected clusterin in CLU1 and CLU2 transfected cells to differ in
cellular locale and size. In support of this prediction, the ATG
translation initiation sites in the CLU1-specific exon 1a as well as
the common exon 2 both satisfy Kozak consensus sequence
requirements (http://bioinfo.iitk.ac.in/AUGPred/). However,
clusterin in CLU1 and CLU2 transfected cells was localized to
the secretory pathway and was equivalent in size under conditions
that would easily discern their predicted five kDa size difference,
especially after PNGase F treatment to remove sugar residues.
Hence, CLU1 and CLU2 produce similar secreted proteins in vitro.
Comparable results were obtained in two cell types, suggesting
that CLU1 and CLU2 generally produce soluble clusterin protein.
The most parsimonious interpretation of these data is that CLU1
translation is generally initiated at the common exon 2 ATG. The
possibility exists that a portion of CLU1 translation is initiated at
the exon 1a ATG at levels too low to be readily detected or that
produce an unstable protein which is rapidly degraded. Distin-
guishing among these possibilities is a future direction for this
work. Overall, we summarize our current results by noting that the
proteins produced from CLU1 and CLU2 in vitro are similar to each
other, and similar in size to those present in human brain, leading
us to interpret our data as supporting the possibility that CLU1 and
CLU2 generally produce secreted clusterin protein in vitro and in
vivo.
A logical extension of the finding that AD risk is reduced with a
genetic variant that correlates with increased CLU expression is
that other factors that increase CLU expression may also reduce
AD risk. Furthermore, since CLU expression is increased in AD
without reversing the disease, we speculate that enhanced CLU
expression reduces AD risk only if CLU expression is increased well
before AD onset, mimicking the likely SNP effects. One possible
modulator of interest is age-dependent changes in sex hormones
since CLU isoforms are differentially regulated by androgens [35].
Stress has also been shown to upregulate CLU in many instances
[36] and may cause the AD-associated increase in CLU observed
here. In terms of possible therapeutic agents, multiple histone
deacetylase inhibitors increase CLU expression robustly in vitro
[37]. Interestingly, one member of this class, valproate, increases
CLU expression in human astrocytes [37] and reduces amyloid
accumulation as well as behavioral deficits in mouse amyloid
models [38,39]. While valproate may also act via other
mechanisms [38], the actions of valproate on CLU expression
may be relevant to its neuroprotection and merit further
exploration to reduce AD risk.
Limitations of this study include that rs11136000 and AD
neuropathological status capture only ,20% of the variance in
CLU expression. Identifying the unknown factors that account for
the additional variance, which could include epigenetic factors,
will facilitate understanding of CLU expression. Moreover,
variability in these factors could facilitate or obscure the SNP
association with CLU1 expression described here, suggesting that
replication of these data in additional samples is necessary for their
Figure 3. CLU1 and CLU2 encoded proteins are localized to the ER and Golgi. SH-SY5Y cells were transfected with vectors encoding CLU1
and CLU2; the resultant clusterin expression was localized by a vector-derived V5 epitope tag. The subcellular localization for both proteins
overlapped with the Golgi, as shown by co-labeling with antibody against TGN46 (A) and with the ER, as shown by co-labeling with an antibody
against calnexin (B).
doi:10.1371/journal.pone.0033923.g003
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acceptance by the research community. Additionally, since the
nuclear form of clusterin arising from an isoform lacking exon 2
has been associated with apoptosis [21,22], this isoform may be
transiently expressed and hence below our limits of detection,
especially in comparison with CLU1 and CLU2.
In conclusion, the AD-protective allele of rs11136000 was
associated with increased expression of CLU1 but not CLU2 in our
dataset. Both CLU1 and CLU2 produce a soluble, secreted
clusterin protein that is similar to that observed in human brain.
Discerning the association between rs11136000 and CLU1
depended upon analyzing these two CLU isoforms separately.
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